| Pharmaceutical Formulations - US & North America | Manufacturing and distribution of OTC and generic prescription drugs primarily in the US market | Established front-end presence in US, regulatory approvals, strong retailer relationships | Retailers, pharmacy chains, and healthcare providers (B2B and B2C) | OTC store brand products with strong shelf presence | 1208 | 46 | Revenue from product sales to retailers and distributors, including private label contracts | Volume-based sales with negotiated retail agreements; focus on high-volume low-price OTC store brands | Expansion in OTC store brand penetration, new product launches, rising seasonal demand | Time-Cap Laboratories’ OTC store brands and generic prescription products |
| Pharmaceutical Formulations - UK & Europe | Manufacture and distribution of non-sterile liquids, ointments, powder sachets, and Rx generics | Regulatory accreditation (MHRA), extensive product portfolio, and local manufacturing facilities | Pharmacies, NHS, healthcare providers, and distributors (B2B) | Proprietary formulations and licensed products under own labels | 1003 | 38 | Product sales primarily to pharmacies and healthcare providers | Contractual sales with healthcare systems, government tenders, and pharmacy chains | Market share gains, new product registrations, and currency tailwinds | Marksans Pharma (UK) Ltd, Bell, Sons & Co. (Druggists) Ltd, Relonchem Ltd |
| Pharmaceutical Formulations - Australia & New Zealand | Marketing and R&D of branded generic and private label OTC products | Market-established brand and relationships with leading retailers | Retail chains and health outlets (B2B and B2C) | Branded generics and private label OTC products | 235 | 9 | Sales of OTC and generic products to retailers and healthcare outlets | Direct sales and private label contracts | Growing OTC demand, product pipeline expansion | Nova Pharmaceuticals Australasia Pty Ltd |
| Pharmaceutical Formulations - Rest of World | Marketing and distribution in MENA and CIS regions | Front-end presence in Middle East, binding distributor contracts | Healthcare providers and distributors in emerging markets (B2B) | Selective product lines with established approvals | 103 | 4 | Sales revenue through regional partners and front-end operations | Focused on capital protection and controlled risk exposure | Gradual market expansion with caution due to geopolitical risks | Access Healthcare for Medical Products L.L.C |
